PMID- 31293419
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 10
DP  - 2019
TI  - Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or 
      beta-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and 
      Meta-Analysis.
PG  - 679
LID - 10.3389/fphar.2019.00679 [doi]
LID - 679
AB  - Background: Brinzolamide as a carbonic anhydrase inhibitor could be combined with 
      other intraocular pressure (IOP) lowering drugs for glaucoma and ocular 
      hypertension (OHT), but the efficacy was controversial. So, this study was used 
      to assess the efficacy and safety of brinzolamide as add-on to prostaglandin 
      analogues (PGAs) or beta-blocker in treating patients with glaucoma or OHT who fail 
      to adequately control IOP. Methods: We searched PubMed, Embase, MEDLINE, Cochrane 
      Library, and clinicaltrials.gov from inception to October 4, 2018. Randomized 
      controlled trials of brinzolamide as add-on to PGAs or beta-blocker for glaucoma and 
      OHT were included. Meta-analysis was conducted by RevMan 5.3 software. Results: A 
      total of 26 trials including 5,583 patients were analyzed. Brinzolamide produced 
      absolute reductions of IOP as an adjunctive therapy for patients with glaucoma or 
      OHT. Brinzolamide and timolol were not significantly different in lowering IOP as 
      add-on to PGAs (9 am: P = 0.07; 12 am: P = 0.66; 4 pm: P = 0.66). Likewise, 
      brinzolamide was as effective as dorzolamide in depressing IOP (9 am: P = 0.59; 
      12 am: P = 0.94; 4 pm: P = 0.95). For the mean diurnal IOP at the end of 
      treatment duration, there were no statistical differences in above comparisons (P 
      > 0.05). Compared with brimonidine (b.i.d.), there was a significant reduction of 
      IOP in brinzolamide (b.i.d.) at 9 am (P < 0.0001); however, the difference was 
      cloudy in thrice daily subgroup (P = 0.44); at 12 am, brinzolamide (b.i.d.) was 
      similar to brimonidine (b.i.d.) in IOP-lowering effect (P = 0.23), whereas 
      brimonidine (t.i.d.) led to a greater effect than brinzolamide (t.i.d.) (P = 
      0.02). At 4 pm, brinzolamide (b.i.d.) was superior IOP-lowering effect compared 
      with brimonidine (b.i.d.) (P = 0.0003); conversely, the effect in brinzolamide 
      (t.i.d.) was lower than brimonidine (t.i.d.) (P < 0.0001). For the mean diurnal 
      IOP, brinzolamide was lower in twice daily subgroup (P < 0.00001); brimonidine 
      was lower in thrice daily subgroup (P < 0.00001). With regard to the safety, 
      brinzolamide and dorzolamide had a higher incidence of taste abnormality; 
      moreover, brinzolamide resulted in more frequent blurred vision; dorzolamide 
      resulted in more frequent ocular discomfort and eye pain. Timolol resulted in 
      more frequent blurred vision and less conjunctival hyperemia. Brimonidine 
      resulted in more frequent ocular hyperemia. As to other adverse events (AEs) 
      (conjunctivitis, eye pruritus, foreign body sensation in eyes, and 
      treatment-related AEs), brinzolamide was similar to other three active 
      comparators. Conclusions: Brinzolamide, as add-on to PGAs or beta-blocker, 
      significantly decreased IOP of patients with refractory glaucoma or OHT and the 
      AEs were tolerable.
FAU - Liu, Yuanzhi
AU  - Liu Y
AD  - Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, 
      Luzhou, China.
FAU - Zhao, Junyi
AU  - Zhao J
AD  - Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, 
      Luzhou, China.
AD  - College of Pharmacy, Southwest Medical University, Luzhou, China.
FAU - Zhong, Xiaoyan
AU  - Zhong X
AD  - Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, 
      Luzhou, China.
FAU - Wei, Qiming
AU  - Wei Q
AD  - Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, 
      Luzhou, China.
FAU - Huang, Yilan
AU  - Huang Y
AD  - Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, 
      Luzhou, China.
LA  - eng
PT  - Systematic Review
DEP - 20190625
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC6603202
OTO - NOTNLM
OT  - brinzolamide
OT  - glaucoma
OT  - ocular hypertension
OT  - prostaglandin analogues
OT  - systematic review
OT  - beta-blocker
EDAT- 2019/07/12 06:00
MHDA- 2019/07/12 06:01
PMCR- 2019/06/25
CRDT- 2019/07/12 06:00
PHST- 2019/02/11 00:00 [received]
PHST- 2019/05/24 00:00 [accepted]
PHST- 2019/07/12 06:00 [entrez]
PHST- 2019/07/12 06:00 [pubmed]
PHST- 2019/07/12 06:01 [medline]
PHST- 2019/06/25 00:00 [pmc-release]
AID - 10.3389/fphar.2019.00679 [doi]
PST - epublish
SO  - Front Pharmacol. 2019 Jun 25;10:679. doi: 10.3389/fphar.2019.00679. eCollection 
      2019.